drugset
drugset / Trial / NCT03870555

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

NCT03870555 ↗

Phase 1 Completed 6 enrolled Millennium Pharmaceuticals, Inc.
RandomizedCrossoverDouble-blindOther

Summary

The purpose of this study is to evaluate the safety, tolerability, and PK of single ascending intravenous doses of TAK-954.

Timeline

Start
2019-03-08
Primary completion
2019-05-16
Completion
2019-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject felcisetrag Small molecule 0.1 mg Intravenous
Subject felcisetrag Small molecule 0.5 mg Intravenous
Subject felcisetrag Small molecule 1 mg Intravenous
Subject felcisetrag Small molecule 2 mg Intravenous

Indications

No indication recorded.